Standard BioTools

Advanced Multiomic Platforms Will Redefine Global Healthcare Standards

AnalystHighTarget

Not Invested

Community Contributor

Published

07 Aug 25

AnalystHighTarget's Fair Value

US$2.00

32.0% undervalued

10 Sep

US$1.36

-23.2%

6.3%

-23.2%

6.3%

You can edit this narrative until Aug 7 9:23 PM. Then, changes will post as Updates.

Author's Valuation

US$232.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$2

32.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-22.20%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.37%

Calculation

US$9.98m

Earnings '28

101.99x

PE Ratio '28

US$1.02b

Market Cap '28

US$1.02b

Market Cap '28

412.76m

No. shares '28

US$2.47

Share Price '28

US$2.47 Share Price '28

Discounted to 2025 @ 7.30% p.a.

US$2.00

Fair Value '25